SFB101
First-in-Class novel drug in preclinical stage
What is a retinal disease?
The retina consists of millions of photoreceptor cells and other nerve cells responsible for receiving and organizing visual signals.1 Population-based studies show retinal diseases prevalence ranging from 5.35% to 21.02% in individuals aged 40 and above.2 Retinal diseases are the primary cause of irreversible blindness in developed countries and the second leading cause of blindness in developing countries, following cataracts.
Unmet Medical Needs
Anti-VEGF therapy reduces vision loss in wet macular degeneration and diabetic retinopathy. However, frequent intravitreal injections increase infection risk and burdens. Urgently needed are effective, patient-friendly drugs to prevent irreversible blindness.
Preclinical Stage
We are co-developing SFB101 with a national research institute in Taiwan, currently in the preclinical stage.
A novel drug candidate potential effective and patient-friendly treat the retinal diseases, preventing blindness.
- Richard H. Masland. Neuron. 2012; 76(2): 266-280.
- Matthew J Burton et al. Lancet Glob Health. 2021; 9(4): e489-e551.